Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2023 Feb;44(2):709-713.
doi: 10.1007/s10072-022-06530-w. Epub 2022 Nov 28.

Cerebrospinal fluid/serum albumin quotient (Q-Alb) is not increased in Alzheimer's disease compared to neurological disease controls: a retrospective study on 276 patients

Eleonora Giacopuzzi Grigoli  1   2 , Federica Solca  2 , Ilaria Milone  2 , Edoardo Nicolò Aiello  2   3 , Antonella Dubini  4 , Antonia Ratti  2   5 , Erminio Torresani  4 , Barbara Poletti  2 , Nicola Ticozzi  2   6 , Emilio Ciusani  7 , Vincenzo Silani  2   6 , Federico Verde  8   9
Affiliations
Comparative Study

Cerebrospinal fluid/serum albumin quotient (Q-Alb) is not increased in Alzheimer's disease compared to neurological disease controls: a retrospective study on 276 patients

Eleonora Giacopuzzi Grigoli et al. Neurol Sci. 2023 Feb.

Abstract

Background: The cerebrospinal fluid (CSF)/serum albumin quotient (Q-Alb) is a marker of the blood-CSF barrier (BCSFB) and possibly of the blood-brain barrier (BBB). The latter is known to be altered in Alzheimer's disease (AD) based on neuropathological and neuroimaging studies. Following investigations performed on clinically diagnosed cohorts, we aimed at comparing Q-Alb in cognitively impaired patients with neurochemical demonstration of AD pathophysiology and neurological disease controls (NDCs).

Methods: We evaluated N = 144 AD patients (MCI, N = 43; AD dementia - ADD, N = 101) and N = 132 NDCs. AD patients were all A + according to the A/T/N framework and were neurochemically classified based on T and N parameters.

Results: Q-Alb did not significantly differ between AD patients and NDCs. Moreover, it was not associated with disease stage (MCI vs. ADD), MMSE score, or CSF AD biomarkers.

Discussion: Our study indicates that BCSFB dysfunction is not a specific feature of AD. When interpreting Q-Alb as a marker of the BBB, the lack of difference from NDCs might be due to BBB dysfunction widely occurring in other neurological, non-degenerative, conditions or - more probably - to low sensitivity of this biochemical parameter towards subtle BBB alterations causing leakage of molecules smaller than albumin. Furthermore, Q-Alb is not associated with the degree of global cognitive deterioration in AD, nor with CSF AD neurochemical biomarkers.

Keywords: Albumin quotient (Q-Alb); Alzheimer’s disease (AD); Blood-brain barrier (BBB); Blood-cerebrospinal fluid barrier (BCSFB); Cerebrospinal fluid (CSF).

PubMed Disclaimer

References

    1. Hegen H, Auer M, Zeileis A, Deisenhammer F (2016) Upper reference limits for cerebrospinal fluid total protein and albumin quotient based on a large cohort of control patients: implications for increased clinical specificity. Clin Chem Lab Med 54(2):285–292. https://doi.org/10.1515/cclm-2015-0253 - DOI
    1. Skillback T, Delsing L, Synnergren J et al (2017) CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients. Neurobiol Aging 59:1–9. https://doi.org/10.1016/j.neurobiolaging.2017.06.028 - DOI
    1. Sweeney MD, Sagare AP, Zlokovic BV (2018) Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol 14(3):133–150. https://doi.org/10.1038/nrneurol.2017.188 - DOI
    1. Janelidze S, Hertze J, Nagga K et al (2017) Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype. Neurobiol Aging 51:104–112. https://doi.org/10.1016/j.neurobiolaging.2016.11.017 - DOI
    1. Musaeus CS, Gleerup HS, Hogh P, Waldemar G, Hasselbalch SG, Simonsen AH (2020) Cerebrospinal fluid/plasma albumin ratio as a biomarker for blood-brain barrier impairment across neurodegenerative dementias. J Alzheimers Dis 75(2):429–436. https://doi.org/10.3233/JAD-200168 - DOI

Publication types

MeSH terms

LinkOut - more resources